The Supreme Court temporarily restored nationwide access to mifepristone by mail, pausing a lower-court ruling that required in-person visits. Justice Samuel Alito issued a one-sentence administrative stay until at least May 11, following a lawsuit by Louisiana that sought to restrict the pill despite the state's near-total abortion ban.

The decision impacts Danco Laboratories and GenBioPro, manufacturers of the medication used in nearly two-thirds of U.S. abortions. About 25% of abortions occur through telemedicine, creating significant market disruption from the Fifth Circuit ruling that would have forced patients to visit providers in person.

The Trump administration faces political challenges as it defends the FDA while appealing to anti-abortion supporters. The case highlights the growing business tensions surrounding reproductive healthcare, with medication abortion representing a substantial market segment worth an estimated $500 million annually before the 2022 Supreme Court decision.